According to Fortune Business Insights, the global CircRNA Synthesis Market was valued at USD 217.54 million in 2025 and is projected to grow from USD 252.61 million in 2026 to USD 835.20 million by 2034, registering a CAGR of 16.12% during the forecast period. Growth is supported by RNA therapeutics research, vaccine development, and advances in gene expression. Circular RNA offers molecular stability and potential for prolonged protein production.
Rising Demand for RNA-Based Therapeutics
Research into cancer immunotherapy, rare diseases, infectious diseases, and regenerative medicine is increasing demand for synthetic circRNA. Its potential for durable protein expression is attracting pharmaceutical and biotechnology developers. Investment in RNA medicines and research collaborations is also supporting demand for reagents, kits, instruments, and custom services.
Advances in Synthesis and Purification Technologies
Researchers are improving circularization, purification, and validation to increase product quality. Automation and specialized reagents can streamline workflows, while custom synthesis services meet specific research needs.
Growing Interest in Personalized Medicine
Precision medicine and tailored therapeutic research are creating opportunities for customized circRNA development. Applications under investigation include oncology, neurological disorders, cardiovascular conditions, and rare genetic diseases.
For detailed market insights, visit: https://www.fortunebusinessinsights.com/circrna-synthesis-market-117527
Expansion of Therapeutic Research
Investment in RNA medicines and vaccines offers opportunities for suppliers providing scalable manufacturing, reliable purification, and high-quality validation.
By Product and Service
Reagents and kits led the market, accounting for approximately 47% of demand in 2025. They support circularization, purification, and validation. Services accounted for around 31%, reflecting demand for custom synthesis and specialist expertise. Instruments represented approximately 22%, including production and quality-control systems.
By Application
Therapeutics development represented approximately 64% of demand in 2025. Researchers are exploring circRNA for potential treatments and vaccine platforms. Drug discovery accounted for around 36%, using synthetic RNA for target validation, gene regulation, and early-stage research.
By End-use
Pharmaceutical and biotechnology companies collectively accounted for approximately 60% of demand. Their research activities support demand for synthesis products and specialized services.